Sun Genomics, Inc.
Classification
Private
About
About
Sun Genomics, Inc., operating under the brand name Flore, is a biotechnology company specializing in personalized probiotics and gut health solutions. With a mission to improve overall health and well-being through a focus on the gut microbiome, Sun Genomics develops innovative probiotic formulations tailored to individual needs. Through advanced DNA sequencing technology and data analytics, the company provides personalized recommendations to optimize gut health and enhance the overall quality of life for its customers. Product/Service Line Breakdown: Gut Microbiome Testing: Sun Genomics offers gut microbiome testing kits that allow customers to collect stool samples at home. These samples are then sent to the company's state-of-the-art laboratory for analysis using advanced DNA sequencing techniques. The testing provides valuable insights into the composition and diversity of the gut microbiome, identifying specific bacterial strains and their abundance. Personalized Probiotics: Based on the results of the gut microbiome analysis, Sun Genomics formulates personalized probiotics specifically tailored to an individual's unique gut microbiome composition. The company combines the insights from DNA sequencing with a proprietary algorithm to identify the most beneficial probiotic strains for each customer. These personalized probiotics are designed to restore and maintain a healthy gut microbiome balance. Probiotic Subscription Service: Sun Genomics operates a subscription-based service where customers receive regular shipments of their personalized probiotics. The subscription model ensures a consistent supply of probiotics to support long-term gut health and wellness. The company may offer different subscription plans based on individual needs and preferences, allowing customers to easily manage their probiotic regimen. Gut Health Consultations: Sun Genomics provides personalized consultations with healthcare professionals specializing in gut health and the gut microbiome. These consultations help customers understand their gut microbiome test results, interpret the data, and receive expert guidance on optimizing gut health. The consultations may also involve dietary and lifestyle recommendations to complement the use of personalized probiotics. Research and Development: Sun Genomics invests in ongoing research and development activities to advance the understanding of the gut microbiome and develop new probiotic formulations. The company collaborates with academic institutions and scientific experts to explore the potential of gut health in various health conditions and disease prevention. The insights gained from research contribute to the continual improvement and innovation of Sun Genomics' products and services. Education and Resources: Sun Genomics is committed to educating the public about the importance of gut health and the role of the gut microbiome in overall well-being. The company provides educational resources, blog articles, and webinars to empower individuals with knowledge about gut health, probiotics, and related topics. These resources aim to support customers in making informed decisions about their gut health journey. Corporate Wellness Programs: Sun Genomics offers corporate wellness programs to businesses interested in promoting employee well-being and productivity through improved gut health. These programs may include gut microbiome testing for employees, personalized probiotic recommendations, educational workshops, and ongoing support for optimizing gut health in the workplace.
Financials
Revenue & Profit
Valuation
Ratios
People
Deals
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
Funding
Keywords
Keywords
Classified
Private